Newsfeeds - Spark Newswire

1 minute read

Axsome Therapeutics Q1 EPS $(1.03) Misses $(1.00) Estimate

Today, 5:22 AM

Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(1.03) per share which missed the analyst consensus estimate of $(1.00) by 3 percent. This is a 32.05 percent decrease over losses of $(0.78) per share from

AXSM

4 minute read

60 Biggest Movers From Yesterday

By Lisa Levin

Today, 5:22 AM

Gainers

AGE

2 minute read

12 Health Care Stocks Moving In Monday’s Intraday Session

By Benzinga Insights

Today, 5:22 AM

ANPC

4 minute read

The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More

By Shanthi Rexaline

Today, 5:22 AM

Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering rate hike fears.

ABBV

4 minute read

54 Biggest Movers From Yesterday

By Lisa Levin

Today, 5:22 AM

Gainers

ACC

2 minute read

12 Health Care Stocks Moving In Tuesday’s Intraday Session

By Benzinga Insights

Today, 5:22 AM

AFIB

3 minute read

38 Stocks Moving In Tuesday’s Mid-Day Session

By Lisa Levin

Today, 5:22 AM

Gainers

ACC

2 minute read

Benzinga’s Daily Brief On Trending Tickers For April 19, 2022: Plug Power, Twitter, Cassava Sciences And More

By AJ Fabino

Today, 5:22 AM

Benzinga’s “Daily Brief On Trending Tickers” features top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items possibly impacting those stocks.

AXSM

1 minute read

Axsome Therapeutics, Inc. Announces It Has Received And Agreed To Postmarketing Requirements/Commitments Proposed By FDA With Respect To NDA For AXS-05

By Bill Haddad

Today, 5:22 AM

Axsome Therapeutics, Inc. (the “Company”) today announced that it has received and agreed to Postmarketing Requirements/Commitments proposed by the U.S. Food and Drug Administration (the “FDA”)

AXSM

5 minute read

Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates

By Shanthi Rexaline

Today, 5:22 AM

Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with it.

ABBV